Incyte INCY underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 8 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 3 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 1 | 4 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $71.82, a high estimate of $92.00, and a low estimate of $60.00. This upward trend is evident, with the current average reflecting a 2.73% increase from the previous average price target of $69.91.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Incyte among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Srikripa Devarakonda | Truist Securities | Lowers | Hold | $74.00 | $83.00 |
| Michael Schmidt | Guggenheim | Raises | Buy | $92.00 | $86.00 |
| Tazeen Ahmad | B of A Securities | Raises | Neutral | $68.00 | $66.00 |
| Brian Abrahams | RBC Capital | Maintains | Sector Perform | $67.00 | $67.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $67.00 | $66.00 |
| James Shin | Deutsche Bank | Raises | Hold | $60.00 | $55.00 |
| David Lebowitz | Citigroup | Raises | Buy | $88.00 | $80.00 |
| Jessica Fye | JP Morgan | Raises | Neutral | $61.00 | $59.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $66.00 | $61.00 |
| Tazeen Ahmad | B of A Securities | Raises | Neutral | $66.00 | $62.00 |
| Jay Olson | Oppenheimer | Lowers | Outperform | $81.00 | $84.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Incyte. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Incyte compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Incyte's stock. This examination reveals shifts in analysts' expectations over time.
For valuable insights into Incyte's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Incyte analyst ratings.
Unveiling the Story Behind Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Breaking Down Incyte's Financial Performance
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Incyte's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.34%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Incyte's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -42.6%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -10.6%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Incyte's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -7.54%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
Analyst Ratings: Simplified
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
